ScholarLens Back to search
2022•healthbook TIMES Oncology HematologyOpen access

Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations

Alfredo Addeo

Open full text 0 citations

Abstract

An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical practice. About 10–20% of patients with NSCLC patients harbor uncommon *EGFR* mutations with varying sensitivity to different EGFR-TKIs. This review presents an overview of the latest clinical data on the potential treatment strategies for NSCLC harboring uncommon *EGFR* mutations.

Open-access reader

About this research paper

What this paper is about

An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical practice. About 10–20% of patients with NSCLC patients harbor uncommon *EGFR* mutations with varying sensitivity to different EGFR-TKIs. This review presents an overview of the latest clinical data on the potential treatment strategies for NSCLC harboring uncommon *EGFR* mutations.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical practice. About 10–20% of patients with NSCLC patients harbor uncommon *EGFR* mutations with varying sensitivity to different EGFR-TKIs. This review presents an overview of the latest clinical data on the potential treatment strategies for NSCLC harboring uncommon *EGFR* mutations.

Key concepts: Afatinib, Erlotinib, Osimertinib, Gefitinib, Medicine, Lung cancer, Epidermal growth factor receptor, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations — Research Paper | ScholarLens